* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Unlicensed Medicines - Neonatal and Paediatric Pharmacists Group
Medical prescription wikipedia , lookup
Drug discovery wikipedia , lookup
Environmental persistent pharmaceutical pollutant wikipedia , lookup
Clinical trial wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Compounding wikipedia , lookup
Prescription drug prices in the United States wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Adherence (medicine) wikipedia , lookup
Pharmaceutical marketing wikipedia , lookup
Pharmacognosy wikipedia , lookup
Prescription costs wikipedia , lookup
Electronic prescribing wikipedia , lookup
Unlicensed Medicines in Paediatrics Is there a problem ? Scottish Neonatal and Paediatric Pharmacist Group National Paediatric PreRegistration Pharmacist Study Day January 2011 AIM To discuss the issues relating to the use of unlicensed medicines in paediatric patients and facilitate discussion of the implications in practice Objectives describe the licensing process identify problems of clinical trials in children examine the extent of the problem discuss seamless care issues pose questions for discussion!!! Kids’ medicine ‘danger’ shock SOME children’s medicines have not been approved for consumption by youngsters according to a report published yesterday. It warns that most medicines either prescribed or sold direct are safe but a minority could do harm in the wrong doses. They are licensed , but only for adults. Extent of unlicensed and off-label prescribing in children 90% 70% care 67% 11% GP of babies in neonatal intensive care of children in paediatric intensive of children in hospital across Europe of children treated at home by their Must use a licensed product when it is suitable Unlicensed and Off-label Medicine Definitions Unlicensed • Extemporaneous dispensing • Pharmaceutical ‘specials’ • Importing medicines licensed in other countries • ‘Named patient’ supplies • Chemicals not licensed at all for human use Off label • • • • • Dose Age of patient Indication Route of administration Contra-indications Risk Assessment of Options Licensed products Route of administration Confidence in manufacturer • • • • Import licensed medicine from QC approved country Pharmaceutical Special (Hospital / Commercial) Extemporaneous Borderline substance Labelling language/ PIL language Finished product testing • Certificate of Analysis • Certificate of Conformity QC Approved importers/ countries • (e.g. within EU, N America, Australia, Japan, Switzerland, New Zealand) The licensing process To market a drug in the UK a pharmaceutical company must obtain a licence from the licensing authority (health ministers guided by the MHRA or EMA) The aim of a licence is to ensure that all medicines in the UK meet acceptable standards of safety, quality and efficacy Extent of a product licence It allows a company to market a drug for; specified conditions in an agreed dose range by a particular route using a tested formulation Based on clinical trial data EMA / MHRA Product Licence Paediatric Investigation Plan (PIP) • Paediatric Regulation to submit a development plan for new medicines • Specific class waivers Paediatric-Use Marketing Authorisation (PUMA) • Already authorise medicine • 10 years market protection Paediatric clinical trials “By an odd and unfortunate twist of fate, infants and children are becoming therapeutic orphans” Shirkey H 1968 Lack of Clinical trials 80% of new drugs had no info in paeds WHY ? ethics long term effects micro-analytical techniques return for investment Directive 89/341/EEC all doctors can prescribe: there is no statutory requirement to disclose to a patient when a drug is unlicensed all unlicensed prescribing / dispensing should be done knowingly(?) the decision to prescribe unlicensed medicines • should be in the best interest of the patient • in accordance with a respectable body of professional opinion Practical Implications Responsibility Liability Patient Information Inappropriate prescribing? Medication Errors • Differing strengths • Differing manufacturer’s Practical Issues Barrier to seamless care Effective communication systems Unlicensed manufacturer’s / suppliers cannot advertise products Dispensing Problems Lack of familiarity Calculations Lack of suitable products- risk assessment of options Only able to order from specific specials suppliers Medication Errors Professional check Cost How Extensive is the problem? Over to you some audience participation please Consider the licensing status of the following medicines for children and neonates Buccal midazolam for seizures Paraldehyde for seizures (rectal) Spironolactone for liver ascites Paracetamol for pyrexia Phenobarbitone for epilepsy EMLA cream for topical anaesthesia Melatonin for sleep disorders in children Ibuprofen for pyrexia